The U.K.'s cost-effectiveness gatekeeper is singing an increasingly harsh tune when it comes to greenlighting cancer drugs, and Celgene's Imnovid is the latest med to get a thumbs-down from the watchdog.
Earlier this month, rumors started swirling that Valeant was talking with its advisers about a potential bid for North Carolina's Salix Pharmaceuticals. Now, it's reportedly one step closer to making that happen--but it may not be alone.
Teva has been investigating for some time whether its business practices abroad have breached the Foreign Corrupt Practices Act (FCPA) and/or local laws. And now, it says it's "likely" they have.
Shire has some hefty sales forecasts in place for 2020, when CEO Flemming Ornskov has said it'll be bringing in a $10 billion top-line haul. Now, after a monster sales vault in 2014, the company is nearly 60% there--but don't expect a repeat growth surge this year, it says.
Behind the usual pharma scenes is a network of doctors, small drugmakers and distributors hawking new dosages of old drugs, a practice that allows physicians to dispense them and reap the profits by billing insurers directly.
Last month, Texas hedge fund manager Kyle Bass said he had pharma and its "questionable" patents in his sights. Now, he's made his first move--and he's said 14 more targets will follow.
After Bayer hives off its plastics business, it's going to remake the rest. The German conglomerate will merge its HealthCare and CropScience divisions into one life-science-focused company, and if sales are any indication, the health side of things will dominate.
SINGAPORE--Hong Kong health facilities say a monthlong outbreak of H3N2 influenza has drained their supply of the drug they use for treatment, Roche's Tamiflu.
SINGAPORE--One of the world's most prestigious medical journals called for India to abandon its current proposal to change the way it regulates drugs and come up with a new plan.
SINGAPORE--China sales of Sanofi's heart and diabetes drugs contributed heavily to sales growth in the country last year, with the market witnessing twice the growth of the rest of the world combined.
SINGAPORE--Here's some expansion news for AbbVie's hepatitis C franchise. The U.S.-based drugmaker has asked Japanese regulators to approve its antiviral cocktail, hoping to grab a piece of that market as it fights for share in the States.
SINGAPORE--Aurobindo Pharma's U.S. unit, AuroMedics Pharma USA, says that if the U.S. FDA manages to speed up its approval process for generic drugs in the coming fiscal year, its earnings could shoot up by half.
When Hospira's proxy was filed last year, CEO F. Michael Ball's $9.9 million in total compensation didn't even rank him among the top 15 highest paid biopharma execs. But with the $15 billion sale of his company to Pfizer, Ball will achieve that goal that CEOs strive for: the payout of the golden parachute. In his case, it is a package that adds up to more than $80 million.
The U.S. Justice Department has slapped AstraZeneca for an alleged kickback scheme. The $7.9 million penalty is peanuts compared with Big Pharma's other marketing settlements--in fact, AstraZeneca's own settlement topped $500 million.
Flying solo isn't always easy, as recent Reckitt Benckiser spinoff Indivior is learning firsthand. The drugmaker reported an 8% decline in 2014 revenues--and the pain won't end there.
Last week, GlaxoSmithKline CEO Andrew Witty told reporters something investors have long been hoping to hear: The company's respiratory newcomers are picking up steam.
Pfizer CEO Ian Read not only isn't done with deals after his Hospira purchase; he's also looking at creative swaps, a la the Novartis-GlaxoSmithKline deals.
The deadline to bid for Dendreon has come and gone, and now that no other qualified bids have come forward, Valeant is walking away victorious.
Gilead Sciences is setting up a new commercial headquarters in London, as a beachhead for growth in the U.K. and beyond. Together with expansions in R&D, the new HQ will double Gilead's work force in England to 600, with 400 of those employees based in London.
Fending off a hostile bid last year from partners Valeant and activist investor Bill Ackman wasn't just a lot of work, according to Allergan CEO David Pyott. It was a full-time job.